Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hallucinogens and Psychedelics01:27

Hallucinogens and Psychedelics

371
Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
371
CNS Stimulants: Psychedelic Agents01:22

CNS Stimulants: Psychedelic Agents

339
Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
339
The Placebo Effect01:54

The Placebo Effect

6.5K
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
6.5K
An Overview of Psychoactive Drugs01:28

An Overview of Psychoactive Drugs

378
Psychoactive drugs impact brain function, influencing perception, mood, consciousness, cognition, and behavior. These substances are grouped based on their effects and the mechanisms by which they act.
Stimulants such as cocaine, amphetamines, and nicotine enhance brain activity, leading to increased alertness, attention, and energy. These drugs typically raise heart rate, blood pressure, and body temperature. While they can induce feelings of euphoria, their misuse can result in severe health...
378
Altered States of Awareness01:06

Altered States of Awareness

715
Altered states of consciousness represent significant deviations from one's normal mental state. These deviations can range from subtle changes in awareness to profound transformations in perception, thought processes, and sensory experiences. Altered states of consciousness can be triggered by various factors, including drug use, meditation, hypnosis, illness, or even intense fatigue.
The ingestion of substances like stimulants or hallucinogens leads to chemical alterations in the brain...
715
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

302
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
302

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Distinct cognitive changes in male patients with obstructive sleep apnoea without co-morbidities.

Frontiers in sleep·2024
Same author

Modafinil for Severe Fatigue in Inflammatory Bowel Disease: A Prospective Case Series.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2024
Same author

Ketamine cystitis following ketamine therapy for treatment-resistant depression - case report.

BMC psychiatry·2024
Same author

Trazodone in the Management of Major Depression Among Elderly Patients with Dementia: A Narrative Review and Clinical Insights.

Neuropsychiatric disease and treatment·2023
Same author

Limited clinical validity of univariate resting-state EEG markers for classifying seizure disorders.

Brain communications·2023
Same author

The effect of a low-calorie diet on depressive symptoms in individuals with overweight or obesity: a systematic review and meta-analysis of interventional studies.

Psychological medicine·2023

Related Experiment Video

Updated: Nov 6, 2025

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
07:30

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

Published on: July 9, 2016

7.4K

Psilocybin: From Serendipity to Credibility?

James J Rucker1,2, Allan H Young1,2

  • 1Department of Psychological Medicine, King's College London, Institute of Psychiatry, Psychology, and Neuroscience, London, United Kingdom.

Frontiers in Psychiatry
|May 10, 2021
PubMed
Summary

Psilocybin shows therapeutic potential in early trials, but widespread use is premature. Unregulated retreat centers offering psilocybin experiences risk misleading the public and undermining scientific credibility.

Keywords:
clinical trialsdepressionpsilocybinretreat centertherapy

More Related Videos

Sexual Development and Ascospore Discharge in Fusarium graminearum
08:20

Sexual Development and Ascospore Discharge in Fusarium graminearum

Published on: March 29, 2012

22.2K
Cercosporin-Photocatalyzed [4+1]- and [4+2]-Annulations of Azoalkenes Under Mild Conditions
07:12

Cercosporin-Photocatalyzed [4+1]- and [4+2]-Annulations of Azoalkenes Under Mild Conditions

Published on: July 17, 2020

6.4K

Related Experiment Videos

Last Updated: Nov 6, 2025

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
07:30

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

Published on: July 9, 2016

7.4K
Sexual Development and Ascospore Discharge in Fusarium graminearum
08:20

Sexual Development and Ascospore Discharge in Fusarium graminearum

Published on: March 29, 2012

22.2K
Cercosporin-Photocatalyzed [4+1]- and [4+2]-Annulations of Azoalkenes Under Mild Conditions
07:12

Cercosporin-Photocatalyzed [4+1]- and [4+2]-Annulations of Azoalkenes Under Mild Conditions

Published on: July 17, 2020

6.4K

Area of Science:

  • Neuroscience
  • Psychopharmacology
  • Clinical Research Ethics

Background:

  • Psilocybin, a compound found in certain mushrooms, has a history of non-medical use.
  • Early-phase clinical trials indicate potential therapeutic utility for psilocybin.
  • Larger, multicenter trials are necessary to confirm efficacy and safety, but these are years from completion.

Purpose of the Study:

  • To evaluate the ethical implications of unregulated psilocybin use in retreat centers.
  • To address the premature generalization of early-phase clinical trial data.
  • To examine the potential risks to public perception and scientific credibility.

Main Methods:

  • Review of existing early-phase clinical trial data on psilocybin.
  • Analysis of ethical principles in human research and treatment development (Nuremberg Code, Kefauver Harris Amendments).
  • Assessment of claims made by commercial retreat centers offering psilocybin experiences.

Main Results:

  • Early-phase trials are not designed for generalization to unregulated settings.
  • Commercial retreat centers are offering psilocybin experiences based on preliminary data.
  • Such practices raise ethical concerns regarding unregulated drug interventions.

Conclusions:

  • Offering psilocybin services before rigorous testing is ethically questionable and potentially misleading.
  • Premature use risks undermining public trust in psilocybin research.
  • Further large-scale clinical trials are essential before widespread adoption.